Antagonist properties of monoclonal antibodies targeting human CD28

References

• Poirier N, Blancho G, Vanhove B. A more selective costimulatory blockade of the CD28-B7 pathway. Transpl Int 2011; 24:2 - 11; http://dx.doi.org/10.1111/j.1432-2277.2010.01176.x; PMID: 20964725
   PubMed Web of Science ®Google Scholar
• Nogid A, Pham DQ. Role of abatacept in the management of rheumatoid arthritis. Clin Ther 2006; 28:1764 - 78; http://dx.doi.org/10.1016/j.clinthera.2006.11.020; PMID: 17212998
   PubMed Web of Science ®Google Scholar
• Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12:210 - 7; http://dx.doi.org/10.1111/j.1600-6143.2011.03785.x; PMID: 21992533
   PubMed Web of Science ®Google Scholar
• Poirier N, Blancho G, Vanhove B. CD28-specific immunomodulating antibodies: what can be learned from experimental models?. Am J Transplant 2012; 12:1682 - 90; http://dx.doi.org/10.1111/j.1600-6143.2012.04032.x; PMID: 22471377
   PubMed Web of Science ®Google Scholar
• Yao S, Zhu Y, Zhu G, Augustine M, Zheng L, Goode DJ, et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011; 34:729 - 40; http://dx.doi.org/10.1016/j.immuni.2011.03.014; PMID: 21530327
   PubMed Web of Science ®Google Scholar
• Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27:111 - 22; http://dx.doi.org/10.1016/j.immuni.2007.05.016; PMID: 17629517
   PubMed Web of Science ®Google Scholar
• Haspot F, Séveno C, Dugast AS, Coulon F, Renaudin K, Usal C, et al. Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells. Am J Transplant 2005; 5:2339 - 48; http://dx.doi.org/10.1111/j.1600-6143.2005.01018.x; PMID: 16162181
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Kundu-Raychaudhuri S, Tamura K, Masunaga T, Kubo K, Hanaoka K, et al. FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model. J Invest Dermatol 2008; 128:1969 - 76; http://dx.doi.org/10.1038/jid.2008.38; PMID: 18337836
   PubMed Web of Science ®Google Scholar
• Perrin PJ, June CH, Maldonado JH, Ratts RB, Racke MK. Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J Immunol 1999; 163:1704 - 10; PMID: 10415078
   PubMed Web of Science ®Google Scholar
• Zhang T, Fresnay S, Welty E, Sangrampurkar N, Rybak E, Zhou H, et al. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant 2011; 11:1599 - 609; http://dx.doi.org/10.1111/j.1600-6143.2011.03624.x; PMID: 21749640
   PubMed Web of Science ®Google Scholar
• Poirier N, Azimzadeh AM, Zhang T, Dilek N, Mary C, Nguyen B, et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2010; 2:17ra10; http://dx.doi.org/10.1126/scitranslmed.3000116; PMID: 20371478
   PubMed Web of Science ®Google Scholar
• Lühder F, Huang Y, Dennehy KM, Guntermann C, Müller I, Winkler E, et al. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 2003; 197:955 - 66; http://dx.doi.org/10.1084/jem.20021024; PMID: 12707299
   PubMed Web of Science ®Google Scholar
• Arad G, Levy R, Nasie I, Hillman D, Rotfogel Z, Barash U, et al. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biol 2011; 9:e1001149; http://dx.doi.org/10.1371/journal.pbio.1001149; PMID: 21931534
   PubMed Web of Science ®Google Scholar
• Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018 - 28; http://dx.doi.org/10.1056/NEJMoa063842; PMID: 16908486
   PubMed Web of Science ®Google Scholar
• Vanhove B, Laflamme G, Coulon F, Mougin M, Vusio P, Haspot F, et al. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 2003; 102:564 - 70; http://dx.doi.org/10.1182/blood-2002-08-2480; PMID: 12649149
   PubMed Web of Science ®Google Scholar
• Shiao SL, McNiff JM, Masunaga T, Tamura K, Kubo K, Pober JS. Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities. Transplantation 2007; 83:304 - 13; http://dx.doi.org/10.1097/01.tp.0000251426.46312.d5; PMID: 17297405
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767 - 71; http://dx.doi.org/10.1038/nbt.1553; PMID: 19620983
   PubMed Web of Science ®Google Scholar
• Liu YD, Chen X, Enk JZ, Plant M, Dillon TM, Flynn GC. Human IgG2 antibody disulfide rearrangement in vivo. J Biol Chem 2008; 283:29266 - 72; http://dx.doi.org/10.1074/jbc.M804787200; PMID: 18713741
   PubMed Web of Science ®Google Scholar
• Yoo EM, Wims LA, Chan LA, Morrison SL. Human IgG2 can form covalent dimers. J Immunol 2003; 170:3134 - 8; PMID: 12626570
   PubMed Web of Science ®Google Scholar
• Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999; 17:780 - 3; http://dx.doi.org/10.1038/11717; PMID: 10429243
   PubMed Web of Science ®Google Scholar
• Yu XZ, Bidwell SJ, Martin PJ, Anasetti C. CD28-specific antibody prevents graft-versus-host disease in mice. J Immunol 2000; 164:4564 - 8; PMID: 10779758
   PubMed Web of Science ®Google Scholar
• Silver PB, Hathcock KS, Chan CC, Wiggert B, Caspi RR. Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol 2000; 165:5041 - 7; PMID: 11046033
   PubMed Web of Science ®Google Scholar
• Dengler TJ, Szabo G, Sido B, Nottmeyer W, Zimmerman R, Vahl CF, et al. Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation. Transplantation 1999; 67:392 - 8; http://dx.doi.org/10.1097/00007890-199902150-00009; PMID: 10030284
   PubMed Web of Science ®Google Scholar
• Guillonneau C, Séveno C, Dugast AS, Li XL, Renaudin K, Haspot F, et al. Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. J Immunol 2007; 179:8164 - 71; PMID: 18056359
   PubMed Web of Science ®Google Scholar
• Haspot F, Villemain F, Laflamme G, Coulon F, Olive D, Tiollier J, et al. Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses. Blood 2002; 99:2228 - 34; http://dx.doi.org/10.1182/blood.V99.6.2228; PMID: 11877302
   PubMed Web of Science ®Google Scholar
• Poirier N, Mary C, Dilek N, Hervouet J, Minault D, Blancho G, et al. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody. Am J Transplant 2012; 12:2630 - 40; http://dx.doi.org/10.1111/j.1600-6143.2012.04164.x; PMID: 22759318
   PubMed Web of Science ®Google Scholar
• Jang MS, Pan F, Erickson LM, Fisniku O, Crews G, Wynn C, et al. A blocking anti-CD28-specific antibody induces long-term heart allograft survival by suppression of the PKC theta-JNK signal pathway. Transplantation 2008; 85:1051 - 5; http://dx.doi.org/10.1097/TP.0b013e31816846f6; PMID: 18408588
   PubMed Web of Science ®Google Scholar
• Clark M, Bindon C, Dyer M, Friend P, Hale G, Cobbold S, et al. The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies. Eur J Immunol 1989; 19:381 - 8; http://dx.doi.org/10.1002/eji.1830190224; PMID: 2522881
   PubMed Web of Science ®Google Scholar
• Poirier N, Blancho G, Vanhove B. Alternatives to calcineurin inhibition in renal transplantation: belatacept, the first co-stimulation blocker. Immunotherapy 2010; 2:625 - 36; http://dx.doi.org/10.2217/imt.10.57; PMID: 20874646
   PubMed Web of Science ®Google Scholar
• Smith BJ, Popplewell A, Athwal D, Chapman AP, Heywood S, West SM, et al. Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem 2001; 12:750 - 6; http://dx.doi.org/10.1021/bc010003g; PMID: 11562193
   PubMed Web of Science ®Google Scholar
• Andres PG, Howland KC, Dresnek D, Edmondson S, Abbas AK, Krummel MF. CD28 signals in the immature immunological synapse. J Immunol 2004; 172:5880 - 6; PMID: 15128767
   PubMed Web of Science ®Google Scholar